Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNO-1355 in Seasonal Allergic Rhinitis
2010-018786-33Phase 2Completed
- Sponsor
- Bionorica
- Start
- Jun 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BNO-1355 in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Bionorica. Primary endpoint: Total Nasal Symptom Score (TNSS) mean 2–4 hours post allergen challenge. Started Jun 2010; status: completed.
02
Drugs
BNO-1355
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2010-018786-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018786-33.